1.Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab.
Shinji OKABAYASHI ; Taku KOBAYASHI ; Tomohisa SUJINO ; Ryo OZAKI ; Satoko UMEDA ; Takahiko TOYONAGA ; Eiko SAITO ; Masaru NAKANO ; Maria Carla TABLANTE ; Shojiroh MORINAGA ; Toshifumi HIBI
Intestinal Research 2017;15(4):535-539
Extracolonic involvement of the gastrointestinal tract is extremely uncommon in ulcerative colitis (UC) and rarely found in the upper gastrointestinal tract or in postoperative cases since it typically responds to steroids. Here we report a case of UC complicated by extensive ileal inflammation that was refractory to steroids. A 20-year-old man was diagnosed with UC of typical pancolitis without ileal involvement and started treatment with pH-dependent mesalazine and oral prednisolone. Although his symptoms transiently resolved, the condition flared when the steroid dose was tapered down. Computed tomography revealed marked thickening of the ileal wall, and capsule endoscopy and balloon-assisted enteroscopy found diffuse mucosal inflammation with ulcers in the ileum. On the contrary, the inflammation in the colon and rectum was improving. Since the response to the second steroid course was inadequate, treatment with adalimumab and 6-mercaptopurine was initiated and finally achieved clinical and endoscopic remission. The investigation of small intestinal lesions is necessary in patients with UC whose clinical deterioration cannot be explained by colonic lesions.
6-Mercaptopurine
;
Adalimumab*
;
Capsule Endoscopy
;
Colitis, Ulcerative*
;
Colon
;
Enteritis*
;
Gastrointestinal Tract
;
Humans
;
Ileum
;
Inflammation
;
Inflammatory Bowel Diseases
;
Mesalamine
;
Prednisolone
;
Rectum
;
Steroids
;
Ulcer*
;
Upper Gastrointestinal Tract
;
Young Adult
2.Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
Keiji YAGISAWA ; Taku KOBAYASHI ; Ryo OZAKI ; Shinji OKABAYASHI ; Takahiko TOYONAGA ; Miki MIURA ; Mari HAYASHIDA ; Eiko SAITO ; Masaru NAKANO ; Hajime MATSUBARA ; Tadakazu HISAMATSU ; Toshifumi HIBI
Intestinal Research 2019;17(1):87-93
BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabilities of these formulations may influence patient adherence; however, they have not been compared to date. This study aimed to evaluate the acceptabilities of the 2 formulations of CR mesalazine in relation to patient adherence using a crossover questionnaire survey. METHODS: UC patients were randomly assigned to 2 groups in a 1:1 ratio. Patients in each group took either 4 g of CR mesalazine tablets or granules for 6 to 9 weeks, and then switched to 4 g of the other formulation for a further 6 to 9 weeks. The acceptability and efficacy were evaluated by questionnaires, and adherence was assessed using a visual analog scale. The difference in acceptabilities between the 2 formulations and its impact on adherence were assessed. RESULTS: A total of 49 patients were prospectively enrolled and 33 patients were included in the analysis. Significantly more patients found the tablets to be less acceptable than the granules (76% vs. 33%, P=0.0005). The granules were preferable to the tablets when the 2 formulations were compared directly (73% vs. 21%, P=0.004), for their portability, size, and numbers of pills. The adherence rate was slightly better among patients taking the granules (94% vs. 91%) during the observation period, but the difference was not significant (P=0.139). CONCLUSIONS: CR mesalazine granules are more acceptable than tablets, and may therefore be a better option for long-term medication.
Colitis, Ulcerative
;
Drug Compounding
;
Humans
;
Medication Adherence
;
Mesalamine
;
Patient Acceptance of Health Care
;
Patient Compliance
;
Prospective Studies
;
Recurrence
;
Tablets
;
Ulcer
;
Visual Analog Scale
3.Gastric Xanthomas and Fundic Gland Polyps as Endoscopic Risk Indicators of Gastric Cancer
Kentaro YAMASHITA ; Ryo SUZUKI ; Toshiyuki KUBO ; Kei ONODERA ; Tomoya IIDA ; Mayuko SAITO ; Yoshiaki ARIMURA ; Takao ENDO ; Masanori NOJIMA ; Hiroshi NAKASE
Gut and Liver 2019;13(4):409-414
BACKGROUND/AIMS: Fundic gland polyps (FGPs), hyperplastic polyps (HPs), and xanthomas (XTs) are common benign gastric lesions that can be diagnosed by endoscopic appearance alone in most cases. The aim of this study was to evaluate associations between gastric cancer and these benign lesions. METHODS: Two expert endoscopists reviewed a series of gastroscopy images. FGPs, HPs, and XTs were diagnosed by endoscopic appearance, whereas all gastric cancers were confirmed pathologically. RESULTS: Of the 1,227 patients reviewed, 114 (9.3%) had a concurrent or past history of gastric cancer. The overall prevalences of FGPs, HPs and XTs were 9.4%, 6.3% and 14.2%, respectively. HPs and XTs coexisted in 1.6% of patients, whereas other combinations were rarer. XTs were observed in 39.3% and 11.5% of patients with and without gastric cancer, respectively (p<0.001). In contrast, no gastric cancer patients had FGPs, whereas 10.4% of patients without cancer had FGPs (p<0.001). The prevalence of HPs was similar between the two groups (8.8% and 6.0% of patients with and without cancer, respectively, p=0.29). Multivariate and Mantel-Haenszel analyses demonstrated that XTs were positively associated and FGPs were negatively associated with gastric cancer. CONCLUSIONS: XTs and FGPs might be useful as endoscopic risk indicators for monitoring gastric cancer.
Gastroscopy
;
Humans
;
Polyps
;
Prevalence
;
Stomach Neoplasms
;
Xanthomatosis
4.Analysis of bone in adenine-induced chronic kidney disease model rats
Hikaru SAITO ; Naohisa MIYAKOSHI ; Yuji KASUKAWA ; Koji NOZAKA ; Hiroyuki TSUCHIE ; Chiaki SATO ; Kazunobu ABE ; Ryo SHOJI ; Yoichi SHIMADA
Osteoporosis and Sarcopenia 2021;7(4):121-126
Objectives:
The purpose of this study is to investigate the stage of chronic kidney disease (CKD) in adenine-induced CKD model rats by serum analyses, and to examine bone mineral density (BMD), bone strength, and microstructure of trabecular and cortical bone in these rats.
Methods:
Eight-week-old, male Wistar rats (n = 42) were divided into 2 groups: those fed a 0.75% adenine diet for 4 weeks until 12 weeks of age to generate CKD model rats (CKD group); and sham rats. The CKD and sham groups were sacrificed at 12, 16, and 20 weeks of age (n = 7 in each group and at 12, 16, and 20 weeks), and various parameters were evaluated, including body weight, renal wet weight, muscle wet weight, renal histology, biochemical tests, BMD, biomechanical testing, and micro-computed tomography (CT). The parameters were compared between the 2 groups at the various time points.
Results:
In the CKD model rats, at 20 weeks of age, serum creatinine, phosphorus, and intact-PTH levels were elevated, and serum calcium levels were normal, indicating that the CKD was stage IV and associated with secondary hyperparathyroidism. Decreased BMDs of the whole body and the femur were observed as bone changes, and micro-CT analysis showed deterioration of bone microstructure of the cortical bone that resulted in decreased bone strength in the cortical and trabecular bone.
Conclusions
These CKD model rats showed stage IV CKD and appear appropriate for evaluating the effects of several treatments for CKD-related osteoporosis and mineral bone disorder.
5.Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats
Shun IGARASHI ; Yuji KASUKAWA ; Koji NOZAKA ; Hiroyuki TSUCHIE ; Kazunobu ABE ; Hikaru SAITO ; Ryo SHOJI ; Fumihito KASAMA ; Shuntaro HARATA ; Kento OKAMOTO ; Keita OYA ; Naohisa MIYAKOSHI
Osteoporosis and Sarcopenia 2023;9(4):121-130
Objectives:
Chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) is associated with an increased risk of fragility fractures. Etelcalcetide (EC) is a treatment for SHPT that reduces serum parathyroid hormone (PTH) levels. However, the effects of combined treatment with osteoporosis drugs such as teriparatide (TPTD) remain unclear. This study investigates the combined effects of EC and TPTD on bone in CKD model rats.
Methods:
The CKD model was established in 8-week-old male Wistar rats by feeding them a 0.75% adenine diet for 4 weeks. At 20 weeks of age, the rats were divided into 4 groups (n = 9–10 in each group): CKD group (vehicle administration), TPTD group (30 μg/kg, 3 times/week), EC group (0.6 mg/kg, daily), and Comb group (TPTD and EC combined). EC was injected for 12 weeks starting at 20 weeks of age, and TPTD was injected for 8 weeks starting at 24 weeks of age. After treatment, the followings were evaluated: bone mineral density, bone strength, biochemical tests, bone and fat histomorphometry, and micro-computed tomography.
Results:
In CKD model rats, the combination of EC and TPTD was more effective in increasing cortical bone thickness and bone strength and inhibiting porosity. In addition, the combined treatment decreased bone marrow adiposity and fibrosis, and it increased bone mass and improved bone microstructure in trabecular bone.
Conclusions
With the observed benefits such as improved bone mass, bone strength, structural properties, and bone marrow adiposity, combination therapy may be a potential way to improve bone fragility in CKD.
6.Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
Keiji YAGISAWA ; Taku KOBAYASHI ; Ryo OZAKI ; Shinji OKABAYASHI ; Takahiko TOYONAGA ; Miki MIURA ; Mari HAYASHIDA ; Eiko SAITO ; Masaru NAKANO ; Hajime MATSUBARA ; Tadakazu HISAMATSU ; Toshifumi HIBI
Intestinal Research 2020;18(3):343-344
7.Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
Shinji OKABAYASHI ; Taku KOBAYASHI ; Eiko SAITO ; Takahiko TOYONAGA ; Ryo OZAKI ; Shintaro SAGAMI ; Masaru NAKANO ; Junichi TANAKA ; Keiji YAGISAWA ; Satoshi KURONUMA ; Osamu TAKEUCHI ; Toshifumi HIBI
Intestinal Research 2019;17(2):218-226
BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis. METHODS: Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day). RESULTS: The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group. CONCLUSIONS: Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.
Colitis, Ulcerative
;
Cytochrome P-450 CYP3A
;
Genotype
;
Humans
;
Pharmacokinetics
;
Polymorphism, Single Nucleotide
;
Prospective Studies
;
Tacrolimus
;
Ulcer
8.Step-by-step instructions for detecting whirlpool sign in adnexal torsion
Ryo HIGASHIDE ; Kazuki SAITO ; Nanako HASHIDO ; Tomonori ISHIKAWA ; Naoyuki MIYASAKA
Journal of Rural Medicine 2023;18(3):189-193
Objective: Adnexal torsion is a common gynecological emergency whose prompt diagnosis is essential because a delay may lead to ovarian dysfunction. Although the whirlpool sign is reliable for diagnosing ovarian cyst torsion, technical difficulties hinder its use by sonographers. Here we developed a systematic approach to visualizing this sign by focusing on the fact that torsion arises from the space between the uterus and the pelvic wall. One must determine the origin of the torsion via transverse imaging of the uterus and follow the twisted ligaments to the ovarian cyst.Patients and Methods: Two women aged 56 (Case 1) and 28 years (Case 2) visited our hospital with lower abdominal pain. Transvaginal ultrasonography showed a 7-cm right ovarian cyst in Case 1 and a 5-cm cyst in the Douglas pouch in Case 2; normal bilateral ovaries and the whirlpool sign were detected in both cases. Under laparoscopic guidance in Cases 1 and 2, an ovarian cyst and a paraovarian cyst were confirmed and removed.Results: Our step-by-step method allowed us to identify the whirlpool sign and confirm adnexal torsion, leading to prompt surgery in both cases.Conclusion: Using a systematic procedure helps less experienced practitioners detect the whirlpool sign.
9.Impact of COVID-19 spread on visit intervals and clinical parameters for patients with periodontitis in supportive periodontal therapy:a retrospective study
Mizuho YAMAZAKI-TAKAI ; Yumi SAITO ; Shoichi ITO ; Moe OGIHARA-TAKEDA ; Tsuyoshi KATSUMATA ; Ryo KOBAYASHI ; Shuta NAKAGAWA ; Tomoko NISHINO ; Namiko FUKUOKA ; Kota HOSONO ; Mai YAMASAKI ; Yosuke YAMAZAKI ; Yuto TSURUYA ; Arisa YAMAGUCHI ; Yorimasa OGATA
Journal of Periodontal & Implant Science 2024;54(2):75-84
Purpose:
This study investigated the relationship between the number of days that hospital visits were postponed and changes in clinical parameters due to the spread of coronavirus disease 2019 (COVID-19), after the Japanese government declared a state of emergency in April 2020.
Methods:
Regarding the status of postponement of appointments, we analyzed the patients who had visited the Nihon University Hospital at Matsudo for more than 1 year for supportive periodontal therapy (SPT) and classified them into low-, moderate- and high-risk subgroups according to the periodontal risk assessment (PRA). Clinical parameters for periodontal disease such as probing depth (PD), full-mouth bleeding score (FMBS), full-mouth plaque score, periodontal inflamed surface area (PISA), and periodontal epithelial surface area (PESA) were analyzed in 2 periods, from October 2019 to March 2020 and after April 2020.Correlation coefficients between days of deferral and the degree of changes in clinical parameters were calculated.
Results:
The mean age of the 749 patients was 67.56±10.85 years, and 63.82% were female.Out of 749 patients, 33.24% deferred their SPT appointments after April 2020. The average total of postponement days was 109.49±88.84. The number of postponement days was positively correlated with changes in average PD (rs=0.474) and PESA (rs=0.443) in the high-risk subgroup of FMBS, and average PD (rs=0.293) and PESA (rs=0.253) in the highrisk subgroup of tooth number (TN). Patients belonging to the high-risk subgroups for both FMBS and TN had a positive correlation between postponement days and PISA (rs=0.56).
Conclusions
The findings, the spread of COVID-19 appears to have extended the visit interval for some SPT patients. Moreover, longer visit intervals were correlated with the worsening of some clinical parameters for SPT patients with high PRA.
10.Impact of COVID-19 spread on visit intervals and clinical parameters for patients with periodontitis in supportive periodontal therapy:a retrospective study
Mizuho YAMAZAKI-TAKAI ; Yumi SAITO ; Shoichi ITO ; Moe OGIHARA-TAKEDA ; Tsuyoshi KATSUMATA ; Ryo KOBAYASHI ; Shuta NAKAGAWA ; Tomoko NISHINO ; Namiko FUKUOKA ; Kota HOSONO ; Mai YAMASAKI ; Yosuke YAMAZAKI ; Yuto TSURUYA ; Arisa YAMAGUCHI ; Yorimasa OGATA
Journal of Periodontal & Implant Science 2024;54(2):75-84
Purpose:
This study investigated the relationship between the number of days that hospital visits were postponed and changes in clinical parameters due to the spread of coronavirus disease 2019 (COVID-19), after the Japanese government declared a state of emergency in April 2020.
Methods:
Regarding the status of postponement of appointments, we analyzed the patients who had visited the Nihon University Hospital at Matsudo for more than 1 year for supportive periodontal therapy (SPT) and classified them into low-, moderate- and high-risk subgroups according to the periodontal risk assessment (PRA). Clinical parameters for periodontal disease such as probing depth (PD), full-mouth bleeding score (FMBS), full-mouth plaque score, periodontal inflamed surface area (PISA), and periodontal epithelial surface area (PESA) were analyzed in 2 periods, from October 2019 to March 2020 and after April 2020.Correlation coefficients between days of deferral and the degree of changes in clinical parameters were calculated.
Results:
The mean age of the 749 patients was 67.56±10.85 years, and 63.82% were female.Out of 749 patients, 33.24% deferred their SPT appointments after April 2020. The average total of postponement days was 109.49±88.84. The number of postponement days was positively correlated with changes in average PD (rs=0.474) and PESA (rs=0.443) in the high-risk subgroup of FMBS, and average PD (rs=0.293) and PESA (rs=0.253) in the highrisk subgroup of tooth number (TN). Patients belonging to the high-risk subgroups for both FMBS and TN had a positive correlation between postponement days and PISA (rs=0.56).
Conclusions
The findings, the spread of COVID-19 appears to have extended the visit interval for some SPT patients. Moreover, longer visit intervals were correlated with the worsening of some clinical parameters for SPT patients with high PRA.